New Product: Sarclisa (isatuximab) 20mg/mL concentrate for solution for infusion

Isatuximab, in combination with pomalidomide and dexamethasone, is licensed for treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Source:

electronic Medicines compendium